Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series

Climb Bio

Climb Bio

CLYM

0.00

The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy volunteers, at the next installment of its R&D Spotlight Series, expected to take place in late summer.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.